SPACs in Biopharma: Boom or Bust?

May 27, 2021 11:00 AM - 11:45 AM

Webinar, click "live-stream" button to view

Add to Calendar 5/27/2021 11:00:00 AM 5/27/2021 11:45:00 AM SPACs in Biopharma: Boom or Bust?

2020 saw a special purpose acquisition company (SPAC) boom in the life sciences industry: 33 biopharma SPACs raised more than $6B globally. Now halfway into 2021, SPACs continue to show promise as a new way for emerging biopharmas to go public, but are they living up to the early hype?

In this virtual Forum, panelists will share their bullish or bearish thoughts on the recent surge in SPACs. Topics will include:

  • The SPAC investment ecosystem
  • Pros/cons about launching via a SPAC
  • Navigating SPAC investing
Webinar, click "live-stream" button to view
Member, Co-chair, Securities & Capital Markets Practice, Mintz
Bill is the Co-chair of the Securities & Capital Markets Practice Group and is a member of the firm's Policy Committee. He has extensive experience representing issuers, investors, and investment banks in structuring and executing IPOs, cross-over investments, alternative public offerings, including APOs, reverse mergers and Form 10 transactions, follow-on public offerings, CMPOs, registered directs, PIPEs, and private placements. Bill represents hedge funds, venture capital firms, and private equity firms in customized investments in public companies, including structured PIPEs and registered directs. Bill also represents public companies in public and private financings, SEC compliance, corporate governance, and general counseling. Bill has extensive experience representing buyers and sellers in M&A transactions, including public company deals, private company deals, and spin-offs. Bill regularly represents domestic and foreign companies, and he is well-versed in issues specific to cross-border deals. Additionally, Bill represents private companies and investors in venture capital transactions.